Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LEVI-04 in Healthy Volunteers and Knee Osteoarthritis
NCT03227796Phase 1Completed
- Sponsor
- Levicept
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LEVI-04 in osteoarthritis (OA) (9 arms), sponsored by Levicept. Primary endpoints: Incidence of treatment emergent adverse events at Day 105, Change from Baseline in neurological assessments - Survey of Autonomic Symptoms at Day 105 and 2 more. Started Jul 2017; status: completed.
02
Drugs
LEVI-04
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03227796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03227796.